A potent and balanced dual PPARα/γ agonist (EC50= 50/21 nM).

A potent AHR (aryl hydrocarbon receptor) agonist that induces degradation of AhR by the ubiquitin-proteasome pathway.

A potent adenosine transport activity of ENT-1 with IC50 of 26.9 nM.

A potent acetylcholinesterase (AChE) inhibitor with IC50 of 1.3 nM.

A potent acetylcholinesterase (AChE) inhibitor with IC50 of 1.3 nM.

A poten and selective, ATP-competitive DNA-PK inhibitor with IC50 of 0.19 uM, Ki of 24 nM.

A poorly reversible TRAAK inhibitor, shows no activity for non-K2P channels (Kv1.2, Slo1 and GIRK2)..

A polyene antifungal antibiotic that works by disrupting the cell membrane of the fungal cells..

A plant metabolite possessing anti-leukemic activity; inhibits the non-receptor kinases, Syk and Lck.

A plant flavonoid that has been found to inhibit cell proliferation by arresting the cell cycle at the G2/M phase.

A plant activator of systemic acquired resistance, boosts the production of herbivore-induced plant volatiles.

A picornavirus replication inhibitor by binding to the hydrophobic pocket within the VP1 coat protein, thus stabilizing the virion and blocking its uncoating..

A phosphate ester prodrug of the HIV-1 protease inhibitor amprenavir with improved solubility..

A phenolic antioxidant and a selective inducer and activator of Nrf2 that ameliorates doxorubicin-induced cardiotoxicity in vivo.

A pH-dependent, GluN2B-selective inhibitor of NMDA receptor with IC50 of 0.19 uM at pH6.9, 10-fold selecivity over brain tissue pH 7.6 (IC50=1.8 uM).

A pesticide agent..

A peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis. .

A partially dueterated analog of Atazanavir, an oral HIV protease inhibitor; A deuterium-containing medicine with improved ADME properties; Compound 120 showed an approximately 50% increase in half life compared with Atazanavir.

A orally active prodrug of LY3020371, which is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, respectively.

A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS..

A nucleoside analogue that shows potent inhibition for replication of several mosquito-borne flaviviruses including DENV and ZIKV.

A novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells.

A novel, specific CD147 inhibitor that can specifically disrupt CD147 dimerization, inhibits the motility and invasion of HCC cells (IC50=7-10 uM).

A novel, potent, selective orally active CCK-2 receptor antagonist with pKi of 8.49 for hCCK2.

A novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with enzyme IC50 of 30 nM, cell IC50 of 7 nM (FcεR1-mediated histamine release in human monocyte-derived mast cells, in the presence of 0.1% albumin).

A novel, potent nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with IC50 of 44 nM.

A novel, potent and selective ALDH1A1 inhibitor with Ki of 300 nM and IC50 of 4.6 uM.

A novel, orally active, small molecule inhibitor of BMI-1 that accelerates BMI-1 degradation, inhibits AML cells growth with IC50 of <100 nM.

A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM.

A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.